Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.52 |
| ▸ | SQLE | Q14534 | 7/20 | 0.50 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12037687 | 1.00 | KMT2A (0.52) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL29662804 | 1.00 | KMT2A (0.52) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL15078582 | 0.84 | — | — | |
| SCHEMBL712008 | 0.84 | — | — | |
| SCHEMBL1204660 | 0.84 | — | — | |
| SCHEMBL900304 | 0.83 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10323892 | 0.83 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL4389533 | 0.83 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL900303 | 0.83 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11042453 | 0.83 | KMT2A (0.74) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828323-B2 | Process for preparation of MK-7 type of vitamin K2 | NATTOPHARMA R & D LTD. (CY) | 2017-11-28 | — | — | US | disclosed |
| US-20170283354-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2017-10-05 | — | — | US | disclosed |
| US-20150291498-A1 | PROCESS FOR PREPARATION OF MK-7 TYPE OF VITAMIN K2 | NATTOPHARMA R&D LTD (CY) | 2015-10-15 | — | — | US | disclosed |
| US-20150210620-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2015-07-30 | — | — | US | disclosed |
| US-9012693-B2 | Process for the preparation of vitamin K2 | KAPPA BIOSCIENCE AS (NO) | 2015-04-21 | — | — | US | disclosed |
| US-20110207967-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | KAPPA BIOSCIENCE AS (NO) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291498-A1 | PROCESS FOR PREPARATION OF MK-7 TYPE OF VITAMIN K2 | SIRT7, PROC, F7 | KMT2A 384/4885MAPT 4863/4885MEN1 38/4885 |
| US-20170283354-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | PROC, VKORC1, VKORC1L1 | KMT2A 206/4885MAPT 4724/4885MEN1 44/4885 |
| US-20110207967-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | PROC, VKORC1, VKORC1L1 | KMT2A 225/4885MAPT 4700/4885MEN1 44/4885 |
| US-20150210620-A1 | PROCESS FOR THE PREPARATION OF VITAMIN K2 | PROC, VKORC1, VKORC1L1 | KMT2A 206/4885MAPT 4724/4885MEN1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.